Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 16.731
Filtrar
2.
Int J Immunopathol Pharmacol ; 35: 20587384211005645, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33779346

RESUMEN

Protective effects of peroxiredoxin 6 (PRDX6) in RIN-m5F ß-cells and of thymulin in mice with alloxan-induced diabetes were recently reported. The present work was aimed at studying the efficiency of thymulin and PRDX6 in a type 1 diabetes mellitus model induced by streptozotocin in mice. Effects of prolonged treatment with PRDX6 or thymic peptide thymulin on diabetes development were evaluated. We assessed the effects of the drugs on the physiological status of diabetic mice by measuring blood glucose, body weight, and cell counts in several organs, as well as effects of thymulin and PRDX6 on the immune status of diabetic mice measuring concentrations of pro-inflammatory cytokines in blood plasma (TNF-α, interleukin-5 and 17, and interferon-γ), activity of NF-κB and JNK pathways, and Hsp90α expression in immune cells. Both thymulin and PRDX6 reduced the physiological impairments in diabetic mice at various levels. Thymulin and PRDX6 provide beneficial effects in the model of diabetes via very different mechanisms. Taken together, the results of our study indicated that the thymic peptide and the antioxidant enzyme have anti-inflammatory functions. As increasing evidences show diabetes mellitus as a distinct comorbidity leading to acute respiratory distress syndrome and increased mortality in patients with COVID-19 having cytokine storm, thymulin, and PRDX6 might serve as a supporting anti-inflammatory treatment in the therapy of COVID 19 in diabetic patients.


Asunto(s)
MAP Quinasa Quinasa 4/metabolismo , FN-kappa B/metabolismo , Peroxiredoxina VI , Transducción de Señal , Factor Tímico Circulante , Animales , Antiinflamatorios/metabolismo , Antiinflamatorios/farmacología , Antioxidantes/metabolismo , Antioxidantes/farmacología , /inmunología , Diabetes Mellitus/tratamiento farmacológico , Diabetes Mellitus/inmunología , Diabetes Mellitus Experimental/inmunología , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Experimental/terapia , Descubrimiento de Drogas , Interferón gamma/sangre , Interleucinas/sangre , Ratones , Peroxiredoxina VI/metabolismo , Peroxiredoxina VI/farmacología , Transducción de Señal/efectos de los fármacos , Transducción de Señal/inmunología , Factor Tímico Circulante/metabolismo , Factor Tímico Circulante/farmacología , Factor de Necrosis Tumoral alfa/sangre
3.
Medicine (Baltimore) ; 100(11): e25045, 2021 Mar 19.
Artículo en Inglés | MEDLINE | ID: mdl-33725979

RESUMEN

ABSTRACT: Malignant neoplasms are the leading cause of death in Korea. We aimed to examine if metformin use in cancer survivors reduces all-cause mortality. This study was retrospectively designed based on data from the Korean National Health Insurance Service-National Health Screening Cohort (HEALS) between 2002 and 2015. The Kaplan-Meier estimator and log-rank test was performed to estimate the survival function according to metformin usage (3721 metformin non-users with diabetes, 5580 metformin users with diabetes, and 24,483 non-diabetic individuals). Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause mortality were calculated using Cox proportional hazards regression models.The median follow-up duration was 4.2 years. The HRs (95% CIs) for all-cause mortality of metformin users and the non-diabetic group were 0.762 (0.683-0.850) and 1.055 (0.966-1.152) in men and 0.805 (0.649-0.999), and 1.049 (0.873-1.260) in women, respectively, compared with metformin non-users among diabetic cancer survivors, in a fully adjusted model. After stratifying metformin users into pre- and post-diagnosis of cancers, adjusted HRs (95% CIs) of pre- and post-diagnosis metformin users for all-cause mortality were 0.948 (0.839-1.071) and 0.530 (0.452-0.621) in men and 1.163 (0.921-1.469) and 0.439 (0.323-0.596) in women, respectively.Metformin use in cancer survivors with diabetes reduced overall mortality rates. In particular, metformin use after cancer diagnosis, not before cancer diagnosis, was inversely associated with overall mortality.Active treatment with metformin for diabetic cancer survivors after cancer diagnosis can improve their survival rates.


Asunto(s)
Diabetes Mellitus/tratamiento farmacológico , Diabetes Mellitus/mortalidad , Hipoglucemiantes/uso terapéutico , Metformina/uso terapéutico , Neoplasias/mortalidad , Adulto , Anciano , Supervivientes de Cáncer/estadística & datos numéricos , Causas de Muerte , Femenino , Estudios de Seguimiento , Humanos , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Programas Nacionales de Salud/estadística & datos numéricos , Neoplasias/complicaciones , Modelos de Riesgos Proporcionales , República de Corea , Estudios Retrospectivos , Resultado del Tratamiento
4.
Zhongguo Zhong Yao Za Zhi ; 46(4): 772-776, 2021 Feb.
Artículo en Chino | MEDLINE | ID: mdl-33645080

RESUMEN

The evaluation standard of LEAD animal model was established according to the understanding of the etiology and pathogenesis of diabetic lower extremity vascular disease based on Chinese and Western medicine. The consistency between the existing LEAD animal model and the clinical characteristics of traditional Chinese and Western medicine was analyzed and evaluated. The advantages and disadvantages of the existing model were compared,the application scope of different models was considered,and the possible improvement methods of the existing model were proposed,so as to provide impetus for the improvement of LEAD animal model.We should reflect more characteristics of traditional Chinese medicine syndromes in the process of model improvement and development,making the LEAD animal model to get closer to clinical features of traditional Chinese and Western medicine.


Asunto(s)
Diabetes Mellitus , Medicamentos Herbarios Chinos , Medicina , Animales , China , Diabetes Mellitus/tratamiento farmacológico , Extremidad Inferior , Medicina China Tradicional
7.
Ann Intern Med ; 174(3): JC26, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33646846

RESUMEN

SOURCE CITATION: Navaneethan SD, Zoungas S, Caramori ML, et al. Diabetes management in chronic kidney disease: synopsis of the 2020 KDIGO Clinical Practice Guideline. Ann Intern Med. 2020. [Epub ahead of print]. 33166222.


Asunto(s)
Diabetes Mellitus , Insuficiencia Renal Crónica , Diabetes Mellitus/tratamiento farmacológico , Humanos , Insuficiencia Renal Crónica/complicaciones , Insuficiencia Renal Crónica/terapia
8.
Rev Med Liege ; 76(2): 93-97, 2021 Feb.
Artículo en Francés | MEDLINE | ID: mdl-33543854

RESUMEN

Patients with diabetes have a higher risk of nonvalvular atrial fibrillation (NVAF), cerebral embolisms and anticoagulant-related intracranial bleeding when compared to nondiabetic patients. Non-vitamin K oral anticoagulants (NOACs) are progressively replacing antivitamin K agents among patients with NVAF. They are as efficacious as warfarin to reduce the risk of cerebral and systemic embolisms while reducing the risk of both severe and cerebral hemorrhages. Four studies reported results of prespecified subanalyses that compared results of efficacy and safety of NOACs (dabigatran, rivaroxaban, apixaban, edoxaban) in patients with and without diabetes, overall with similar results in both subgroups. ENGAGE AF-TIMI 48 is the only trial that reported a significant reduction of severe hemorrhages with edoxaban compared with warfarin in diabetic patients with NVAF.


Asunto(s)
Fibrilación Atrial , Diabetes Mellitus , Accidente Cerebrovascular , Administración Oral , Anticoagulantes/efectos adversos , Fibrilación Atrial/complicaciones , Fibrilación Atrial/tratamiento farmacológico , Diabetes Mellitus/tratamiento farmacológico , Humanos , Accidente Cerebrovascular/etiología , Accidente Cerebrovascular/prevención & control , Warfarina/uso terapéutico
9.
J Assoc Physicians India ; 69(2): 71-72, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-33527819

RESUMEN

Fungi in the class of zygomycetes usually produce serious infections in diabetics and immunocompromised hosts. Cutaneous zygomycosis is a less common form, with an unpredictable extent of anatomical involvement and clinical course1.¹ Here, we report a case of primary cutaneous zygomycosis caused by saksaenea vasiformis as posttraumatic complications in a diabetic female. Zygomycosis was suspected and specimens from the surgical debridement were examined by microbiological and histopathological studies for conforming the clinical diagnosis. Rapid diagnosis, liposomal amphotericin B, and proper debridement of affected tissue are necessary to avoid a fatal outcome.


Asunto(s)
Dermatomicosis , Diabetes Mellitus , Zigomicosis , Antifúngicos/uso terapéutico , Dermatomicosis/diagnóstico , Dermatomicosis/tratamiento farmacológico , Diabetes Mellitus/tratamiento farmacológico , Femenino , Hongos , Humanos , Huésped Inmunocomprometido , Zigomicosis/diagnóstico
10.
Niger J Clin Pract ; 24(2): 277-281, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-33605920

RESUMEN

Aims: The aim of this study was to assess the effect of intraarticular glucocorticoid injections on blood glucose levels in diabetes mellitus (DM) and non-DM patients with adhesive capsulitis of the shoulder and investigate the risk factors for hyperglycemia. Methods: The study included 40 DM and 38 non-DM patients. The DM status, HbA1c levels, baseline fasting blood glucose (FBG) level, and post-injection 1-, 7-, 15-, and 21-day FBG levels were evaluated retrospectively. Results: The FBG levels were significantly higher 1 and 7 day after the glucocorticoid injection as compared with the baseline levels (P = 0.001 and <0.001, respectively). The increase was greatest in DM patients and then returned to baseline levels 15-day post-injection. In terms of the mean difference in post-injection and baseline FBG levels, the increase on day 1 was statistically significantly greater in the DM group as compared with that in the non-DM group (P = 0.01). Linear regression model showed that only the baseline FBG level predicted the glucose level 1-day post-treatment (ß = 0.839, P < 0.01). Conclusion: Intraarticular glucocorticoid injections can safely be administered as a treatment for adhesive capsulitis of the shoulder in patients with well-controlled DM. Baseline FBG levels may predict peak blood glucose levels in patients with well-controlled DM. We recommend that DM patients with adhesive capsulitis should undergo frequent monitoring of blood glucose in the 2 week following intraarticular glucocorticoid injection treatment.


Asunto(s)
Bursitis , Diabetes Mellitus , Glucemia , Bursitis/tratamiento farmacológico , Diabetes Mellitus/tratamiento farmacológico , Diabetes Mellitus/epidemiología , Glucocorticoides , Humanos , Estudios Retrospectivos
11.
Int J Nanomedicine ; 16: 1261-1280, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33628020

RESUMEN

Diabetes mellitus is a major threat to human health. Both its incidence and prevalence have been rising steadily over the past few decades. Biomacromolecular agents such as insulin and glucagon-like peptide 1 receptor agonists are commonly used hypoglycemic drugs that play important roles in the treatment of diabetes. However, their traditional frequent administration may cause numerous side effects, such as pain, infection or local tissue necrosis. To address these issues, many novel subcutaneous delivery systems have been developed in recent years. In this review, we survey recent developments in subcutaneous delivery systems of biomacromolecular hypoglycemic drugs, including sustained-release delivery systems and stimuli-responsive delivery systems, and summarize the advantages and limitations of these systems. Future opportunities and challenges are discussed as well.


Asunto(s)
Diabetes Mellitus/tratamiento farmacológico , Sistemas de Liberación de Medicamentos , Sustancias Macromoleculares/química , Tejido Subcutáneo/fisiología , Animales , Humanos , Hipoglucemiantes/química , Hipoglucemiantes/uso terapéutico , Nanopartículas/química
12.
Cell Prolif ; 54(3): e12982, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-33554390

RESUMEN

Diabetes mellitus (DM) is a chronic metabolic disorder with various complications that poses a huge worldwide healthcare burden. Wounds in diabetes, especially diabetic foot ulcers (DFUs), are difficult to manage, often leading to prolonged wound repair and even amputation. Wound management in people with diabetes is an extremely clinical and social concern. Nowadays, physical interventions gain much attention and have been widely developed in the fields of tissue regeneration and wound healing. Magnetic fields (MFs)-based devices are translated into clinical practice for the treatment of bone diseases and neurodegenerative disorder. This review attempts to give insight into the mechanisms and applications of MFs in wound care, especially in improving the healing outcomes of diabetic wounds. First, we discuss the pathological conditions associated with chronic diabetic wounds. Next, the mechanisms involved in MFs' effects on wounds are explored. At last, studies and reports regarding the effects of MFs on diabetic wounds from both animal experiments and clinical trials are reviewed. MFs exhibit great potential in promoting wound healing and have been practised in the management of diabetic wounds. Further studies on the exact mechanism of MFs on diabetic wounds and the development of suitable MF-based devices could lead to their increased applications into clinical practice.


Asunto(s)
Diabetes Mellitus/tratamiento farmacológico , Pie Diabético/tratamiento farmacológico , Campos Magnéticos , Cicatrización de Heridas/efectos de los fármacos , Experimentación Animal , Animales , Enfermedad Crónica , Humanos
14.
BMJ Open ; 11(1): e043590, 2021 01 19.
Artículo en Inglés | MEDLINE | ID: mdl-33468529

RESUMEN

INTRODUCTION: The COVID-19 pandemic resulted in a national lockdown in India from midnight on 25 March 2020, with conditional relaxation by phases and zones from 20 April. We evaluated the impact of the lockdown in terms of healthcare provisions, physical health, mental health and social well-being within a multicentre cross-sectional study in India. METHODS: The SMART India study is an ongoing house-to-house survey conducted across 20 regions including 11 states and 1 union territory in India to study diabetes and its complications in the community. During the lockdown, we developed an online questionnaire and delivered it in English and seven popular Indian languages (Hindi, Tamil, Marathi, Telegu, Kannada, Bengali, Malayalam) to random samples of SMART-India participants in two rounds from 5 May 2020 to 24 May 2020. We used multivariable logistic regression to evaluate the overall impact on health and healthcare provision in phases 3 and 4 of lockdown in red and non-red zones and their interactions. RESULTS: A total of 2003 participants completed this multicentre survey. The bivariate relationships between the outcomes and lockdown showed significant negative associations. In the multivariable analyses, the interactions between the red zones and lockdown showed that all five dimensions of healthcare provision were negatively affected (non-affordability: OR 1.917 (95% CI 1.126 to 3.264), non-accessibility: OR 2.458 (95% CI 1.549 to 3.902), inadequacy: OR 3.015 (95% CI 1.616 to 5.625), inappropriateness: OR 2.225 (95% CI 1.200 to 4.126) and discontinuity of care: OR 6.756 (95% CI 3.79 to 12.042)) and associated depression and social loneliness. CONCLUSION: The impact of COVID-19 pandemic and lockdown on health and healthcare was negative. The exaggeration of income inequality during lockdown can be expected to extend the negative impacts beyond the lockdown.


Asunto(s)
/prevención & control , Prestación de Atención de Salud/normas , Diabetes Mellitus/psicología , Salud Mental , Aislamiento Social/psicología , Adulto , Anciano , Estudios Transversales , Diabetes Mellitus/tratamiento farmacológico , Femenino , Servicios de Salud , Humanos , India , Modelos Logísticos , Soledad , Masculino , Persona de Mediana Edad , Análisis Multivariante , Encuestas y Cuestionarios
15.
Food Chem ; 347: 129056, 2021 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-33476922

RESUMEN

Flavonoid compounds have anti-diabetic activity, which can control blood glucose levels by inhibiting α-glucosidase activity. In this paper, the inhibition mechanisms between four flavonoid compounds and α-glucosidase were studied by multispectroscopic methods and molecular docking. The results showed that the inhibitory activities of flavonoid compounds were higher than that of acarbose, and the sequence of inhibition effect was scutellarein > nepetin > apigenin > hispidulin > acarbose. Also, the synergistic effects of flavonoid compounds combined with acarbose on inhibiting α-glucosidase activity were observed. The fluorescence results showed that flavonoid compounds combined with α-glucosidase to form a stable complex. And the spectral analysis indicated that the microenvironmental and secondary structure of α-glucosidase were changed. The present study demonstrated that the molecular structure of flavonoid compounds played an important role in the inhibition process, namely, scutellarein with more hydroxyl groups on the A-ring might serve as the most effective α-glucosidase inhibitor.


Asunto(s)
Acarbosa/química , Flavonoides/química , Inhibidores de Glicósido Hidrolasas/química , alfa-Glucosidasas/química , Acarbosa/metabolismo , Apigenina/química , Apigenina/metabolismo , Sitios de Unión , Diabetes Mellitus/tratamiento farmacológico , Sinergismo Farmacológico , Flavonas/química , Flavonas/metabolismo , Flavonoides/metabolismo , Flavonoides/uso terapéutico , Inhibidores de Glicósido Hidrolasas/metabolismo , Inhibidores de Glicósido Hidrolasas/uso terapéutico , Humanos , Cinética , Simulación del Acoplamiento Molecular , Termodinámica , alfa-Glucosidasas/metabolismo
16.
Carbohydr Polym ; 256: 117504, 2021 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-33483027

RESUMEN

Oral administration of insulin (INS) would represent a revolution in the treatment of diabetes, considering that this route mimics the physiological dynamics of endogenous INS. Nano- and microencapsulation exploiting the advantageous polysaccharides properties has been considered an important technological strategy to protect INS against harsh conditions of gastrointestinal tract, in the same time that improve the permeability via transcellular and/or paracellular pathways, safety and in some cases even selectivity for targeting delivery of INS. In fact, some polysaccharides also give to the systems functional properties such as pH-responsiveness, mucoadhesiveness under specific physiological conditions and increased intestinal permeability. In general, all polysaccharides can be functionalized with specific molecules becoming more selective to the cells to which INS is delivered. The present review highlights the advances in the past 10 years on micro- and nanoencapsulation of INS exploiting the unique natural properties of polysaccharides, including chitosan, starch, alginate, pectin, and dextran, among others.


Asunto(s)
Diabetes Mellitus Experimental/tratamiento farmacológico , Diabetes Mellitus/tratamiento farmacológico , Sistemas de Liberación de Medicamentos/métodos , Hipoglucemiantes/farmacocinética , Insulina/farmacocinética , Nanopartículas/química , Administración Oral , Alginatos/química , Animales , Quitosano/química , Dextranos/química , Diabetes Mellitus/metabolismo , Diabetes Mellitus/patología , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Experimental/patología , Composición de Medicamentos/métodos , Liberación de Fármacos , Humanos , Hipoglucemiantes/metabolismo , Insulina/metabolismo , Mucosa Intestinal/metabolismo , Nanopartículas/administración & dosificación , Pectinas/química , Permeabilidad , Almidón/química
18.
Life Sci ; 270: 118966, 2021 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-33482185

RESUMEN

AIMS: Beinaglutide has been approved for glucose lowering in type 2 diabetes mellitus (T2DM) in China. In addition to glycemic control, significant weight loss is observed from real world data. This study is designed to investigate the pharmacological and pharmacokinetic profiles of beinaglutide in different models. METHODS: The pharmacological efficacy of beinaglutide was evaluated in C57BL/6 and ob/ob mice after single administration. Pharmacokinetic profiles in mice were investigated after single or multiple administration. Sub-chronic pharmacological efficacy was investigated in ob/ob mice for two weeks treatment and diet-induced ob/ob mice model of nonalcoholic steatohepatitis (NASH) for four weeks treatment. KEY FINDINGS: Beinaglutide could dose-dependently reduce the glucose levels and improve insulin secretion in glucose tolerance tests, inhibit food intake and gastric emptying after single administration. At higher doses, beinaglutide could inhibit food intake over 4 h, which results in weight loss in ob/ob mice after about two weeks treatment. No tachyphylaxis is observed for beinaglutide in food intake with repeated administration. In NASH model, beinaglutide could reduce liver weight and hepatic steatosis and improve insulin sensitivity. Signiant changes of gene levels were observed in fatty acid ß-oxidation (Ppara, Acadl, Acox1), mitochondrial function (Mfn1, Mfn2), antioxidation (Sod2), Sirt1, and et al. SIGNIFICANCE: Our results characterize the pharmacological and pharmacokinetic profiles of beinaglutide in mice and supported that chronic use of beinaglutde could lead to weight loss and reduce hepatic steatosis, which suggest beinaglutide may be effective therapy for the treatment of obesity and NASH.


Asunto(s)
Diabetes Mellitus/metabolismo , Péptido 1 Similar al Glucagón/análogos & derivados , Hipoglucemiantes/farmacología , Enfermedad del Hígado Graso no Alcohólico/tratamiento farmacológico , Obesidad/metabolismo , Fragmentos de Péptidos/farmacología , Animales , Antioxidantes/farmacología , Complicaciones de la Diabetes/tratamiento farmacológico , Diabetes Mellitus/tratamiento farmacológico , Péptido 1 Similar al Glucagón/metabolismo , Péptido 1 Similar al Glucagón/farmacología , Hipoglucemiantes/metabolismo , Insulina/metabolismo , Resistencia a la Insulina , Leptina/metabolismo , Liraglutida/farmacología , Cirrosis Hepática/metabolismo , Cirrosis Hepática/patología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Obesos , Enfermedad del Hígado Graso no Alcohólico/metabolismo , Obesidad/complicaciones , Oxidación-Reducción , PPAR alfa/metabolismo , Fragmentos de Péptidos/química , Pérdida de Peso/efectos de los fármacos
20.
Yakugaku Zasshi ; 141(1): 15-24, 2021.
Artículo en Japonés | MEDLINE | ID: mdl-33390442

RESUMEN

Iminosugars are one of the compounds that mimic the structure of monosaccharides. Such sugar mimics have the ability to effectively and specifically inhibit various glycosidases and glycosyltransferases. After studying iminopyranose, miglitol, which has α-glucosidase inhibitory activity, was approved and used in the clinical treatment of diabetes. This study focused on l-iminofuranose derivatives to develop new anti-diabetic drug. As a result, it was found that l-iminofuranose having an alkyl group at C1 position show potent α-glucosidase inhibitory activity. Further structural-activity relationship studies were conducted, and interesting findings were obtained. This paper describes the details of those research developments.


Asunto(s)
1-Desoxinojirimicina/análogos & derivados , Diabetes Mellitus/tratamiento farmacológico , Inhibidores de Glicósido Hidrolasas , Hipoglucemiantes , Iminopiranosas/síntesis química , Iminopiranosas/farmacología , 1-Desoxinojirimicina/síntesis química , 1-Desoxinojirimicina/química , 1-Desoxinojirimicina/farmacología , 1-Desoxinojirimicina/uso terapéutico , Animales , Humanos , Iminopiranosas/química , Iminopiranosas/uso terapéutico , Relación Estructura-Actividad , alfa-Glucosidasas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...